BioMedNewsBreaks

TuesdaySep 28, 2021 11:25 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) to Present at Benzinga Healthcare Small Cap Conference

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research in psychedelics, today announced that its CEO and President Kelsey Ramsden will present and participate in one-on-one investor meetings at the Benzinga Healthcare Small Cap Conference. The event is scheduled to be held virtually on Sept. 29-30, 2021, with Ramsden’s presentation to begin at 4:00 p.m. ET on Wednesday, Sept. 29. Interested parties should visit https://ibn.fm/Wpkw4 to register for the event. In addition, the company announced it has granted a total of 10,000 stock options to certain employees pursuant to the terms…

Continue Reading

MondaySep 27, 2021 2:37 pm

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Launch of the ‘Desire Project’

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research in psychedelics, today unveiled its “Desire Project,” a clinical research program focused on the treatment of female hypoactive sexual desire disorder with MDMA-assisted psychotherapy. According to the update, the research program will mark the first psychedelic-based treatment program targeted at addressing what is clinically known as Hypoactive Sexual Desire Disorder (“HSDD”), a common sexual disorder characterized by persistent low sexual desire and emotional distress not attributable to an existing medical condition or relationship issue. Current estimates indicate that HSDD affects 10% of…

Continue Reading

MondaySep 27, 2021 1:08 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Eyes Commercial Plans to Become B2B Wholesale Supplier of Rare Cannabinoids

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company based in British Columbia, Canada, is focused on advancing a pipeline of cannabinoid-based pharmaceutical drug candidates. The company is developing a proprietary cannabinoid synthesis manufacturing system known as IntegraSyn(TM), which is designed to advance rare and lesser-known cannabinoid production to commercial levels. A recent article discussing this quotes InMed CEO Eric A. Adams. “The next key milestone is to manufacture our first large-scale batch through a pharma-grade-ready process in the coming months. We will continue to optimize the process and scale up the IntegraSyn process into larger vessels,” Adams said in a recent…

Continue Reading

MondaySep 27, 2021 12:34 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Enters Strategic Commercial Agreement with UK Licensee

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced its entry into a global commercial contract with MySugarWatch DuoPack Limited (“MSW-DP”). Under the agreement, the continuous glucose monitor (“CGM”) and sensors will be provided as duo packs with prescription only medicines that are widely prescribed for people with type 2 diabetes. MSW-DP has been granted global rights to the sugarBEAT(R) non-invasive CGM devices and sensors, to be provided solely as duo packs with these medicines, under the terms of the agreement, which Nemaura will…

Continue Reading

MondaySep 27, 2021 11:58 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Working to Bring Psychedelic Treatments Closer to the People

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is contributing to the ongoing conversation around the use of psychedelics in the field of medicine, thereby stamping its position as a leader in the psychedelic renaissance. This follows efforts by the scientific community in the 21st century to prove the potential of psychedelics to rewire or repair circuits in the brain. Specifically, Tryp is bringing light to psilocybin usage in diseases with high unmet needs, including chronic pain, through its Psilocybin-For Neuropsychiatric Disorders (TM) (“PFN”) program. “With its three strategic initiatives — develop, protect and monetize — Tryp remains committed to utilizing FDA’s…

Continue Reading

FridaySep 24, 2021 1:37 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) CDA Technology Detects Risk of Over 25 Different Cancer Types

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a recognized innovator and leader in the field of early cancer screening and detection. Its core product and proven revenue generator, the pioneering Cancer Differentiation Analysis (“CDA”) platform, offers novel capabilities by looking for signals to help it assess the risk of cancer occurring before a tumor has developed. This approach is unlike the blood sample-based cancer screenings, which generally target protein-based biomarkers, genomic signals, such as circulating tumor DNA (“ct-DNA”), circulating in the bloodstream to determine if a cancer exists and is spreading.…

Continue Reading

FridaySep 24, 2021 12:54 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Release FY 2021 Financial Report and Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has released its financial results and corporate update for FY 2021. In addition, the company announced a conference call and webcast, in which company leadership will discuss the report. Interested parties can access a replay of the webcast for 90 days. Corporate highlights of the report include the definitive agreement the company entered to acquire BayMedica Inc., a private company specializing in the manufacture and commercialization of rare cannabinoids; the announcement that INM’s IntegraSyn(TM) cannabinoid manufacturing approach had achieved a level of 2g/L cannabinoid yield,…

Continue Reading

ThursdaySep 23, 2021 2:21 pm

BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) Proprietary Brain Diagnostics Devices Positioned to Profoundly Shift EEG Market

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is leveraging artificial intelligence (“AI”) and machine learning (“ML”) to improve diagnostic capability using a database of biomarkers that collect data on both normal and abnormal brain information. Brain Scientific’s use of AI and ML is part of its overall strategy to penetrate the rapidly growing electroencephalogram (“EEG”) market. The strategy includes developing its patented FDA-cleared NeuroCap(TM) and NeuroEEG(TM) devices. NeuroCap is a disposable pre-gelled EEG headset with 22 electrodes and 19 active EEG channels that can be used to record EEGs in nearly any setting.…

Continue Reading

ThursdaySep 23, 2021 9:54 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Forms Medical Consortium to Advance OSA Technology

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced the official formation of the Vivos Medical Consortium. According to the update, this physician working group, led by Drs. Clete Kushida of Stanford University and Cecilia Wu of the University of Alberta, will collaborate to advance Vivos’ OSA technology capabilities. “Every specialty in medicine deals with the negative impact of obstructive sleep apnea in some way, with the end stage of untreated sleep apnea including diminished quality of life,…

Continue Reading

WednesdaySep 22, 2021 2:26 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) to Present at Wall Street Reporter’s ‘Next Super Stock’ Livestream Conference

RYAH Group (CSE: RYAH) today announced that its Chief Executive Officer Gregory Wagner will be presenting at Wall Street Reporter's "Next Super Stock" livestream conference on Thursday, Sept. 23, 2021. The online event is expected to give the investment community and existing shareholders an opportunity to interact in real time with Wagner and learn about the company and its operations. Wagner’s presentation is scheduled to begin at 1:00 ET on the day of the conference, during which he will highlight RYAH’s experience and mission, and, time permitting, open the floor for questions. Interested parties should visit https://ibn.fm/K0MtA to ensure access…

Continue Reading